Recognizing Progressive Multifocal Leukoencephalopathy in Tysabri Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Understanding the Risk-Benefit Framework for Tysabri

If you or a loved one is taking Tysabri, understanding the early signs of Progressive Multifocal Leukoencephalopathy (PML) is critical. The medical community has long recognized that prompt identification of PML symptoms can significantly influence outcomes. This page covers the clinical signals that may indicate PML and the typical timeline of symptom progression.

Find Out If You Qualify for Compensation →

Tysabri-Associated PML: Clinical Evidence and Risk Factors

Tysabri (natalizumab) is a monoclonal antibody indicated for the treatment of multiple sclerosis and Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus (JCV). The long-term outcome of PML in patients treated with Tysabri is generally poor, with the condition usually leading to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals. In Tysabri-treated patients, the infection results from reactivation of latent JCV, which is normally controlled by the immune system. The clinical presentation of PML can be variable, often including progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis relies on clinical suspicion, brain MRI findings, and detection of JCV DNA in cerebrospinal fluid. Early recognition is critical because the condition can rapidly worsen. Three primary risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Prognosis and Long-Term Outcomes of PML After Tysabri

The prognosis for patients who develop PML is grave. The condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 patients with multiple sclerosis treated for a median of 120 weeks; these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 patients with Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These data underscore the severity of the risk, even with relatively short exposure. The timeline between Tysabri exposure and documented harm can vary. PML has been reported during treatment and also following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This highlights the need for continued monitoring for at least six months after stopping the drug. Healthcare professionals should monitor patients on Tysabri for any new sign or symptom that may be suggestive of PML, and dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The adequacy of warnings regarding Tysabri and PML is addressed through a boxed warning in the prescribing information, which clearly states that Tysabri increases the risk of PML and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also specifies the known risk factors and instructs healthcare professionals to monitor patients and withhold the drug at the first sign of PML. Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program is designed to ensure that patients and prescribers are informed of the risks and that appropriate monitoring occurs. For affected patients, prognosis-related considerations are critical. Once PML develops, treatment options are limited and focus on supportive care and immune reconstitution, often by discontinuing Tysabri. However, even with prompt discontinuation, the outcome is frequently poor. The risk of PML must be weighed against the therapeutic benefits of Tysabri for each individual patient, taking into account the identified risk factors. The boxed warning emphasizes that these factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In summary, the long-term outcome of PML after Tysabri treatment is typically severe, with high rates of death or permanent disability. The risk is increased by anti-JCV antibody positivity, longer treatment duration, and prior immunosuppressant use. PML can occur during treatment or after discontinuation, necessitating prolonged monitoring. The prescribing information includes strong warnings and a restricted distribution program to mitigate risk, but the prognosis for affected patients remains poor.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for PML after Tysabri treatment?

The long-term outcome of PML in patients treated with Tysabri is generally poor, with the condition usually leading to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Even with prompt discontinuation of Tysabri, the outcome is frequently poor, and treatment options are limited to supportive care and immune reconstitution.

What are the main risk factors for developing PML while on Tysabri?

Three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML.

Can PML occur after stopping Tysabri?

Yes, PML has been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This highlights the need for continued monitoring for at least six months after stopping the drug.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Tysabri Prescribing Information

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.